Stopping graft-versus-host disease by targeting tissue-resident T cells
Official title: Graft-versus-Host Disease: Local Maintenance by Tissue Resident Progenitor T cells
Funded at University of Pittsburgh at Pittsburgh · NIH-11261635 · Data updated 2026-11-12
This research tests whether long-lived T cells that live inside organs keep causing graft-versus-host disease in people who received donor stem cell transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | August 15, 2018 |
| Project end | November 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $767,316 |
| NIH project number | 5R01HL143349-06 |
| Project ID | NIH-11261635 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who have received an allogeneic (donor) hematopoietic stem cell transplant and have ongoing or recurrent GVHD would be most relevant.
✕Less likely to help
People who have never had a donor stem cell transplant or whose health problems are unrelated to GVHD are unlikely to benefit directly.
What this research studies
Researchers are exploring whether GVHD continues because alloreactive T cells that stay in tissues keep causing damage without new input from lymph nodes. They use mouse models with labeled T cell clones and parabiosis to track where T cells come from and whether tissue-resident progenitor T cells keep producing new attackers. The team analyzes T cell clones and behavior to identify cellular targets that could be blocked inside affected organs. Results could point toward treatments that stop organ attacks while keeping the transplant's cancer-fighting benefits.
Why it matters
Potential benefit: Could lead to treatments that stop ongoing organ damage from GVHD while preserving the beneficial graft-versus-leukemia effect.
How similar studies have gone: Existing GVHD treatments broadly suppress T cells, but specifically targeting tissue-resident progenitor T cells is a newer idea with limited clinical testing to date.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Shlomchik, Warren D — University of Pittsburgh at Pittsburgh
- Study coordinator: Shlomchik, Warren D
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Microbiome-based therapy for treatment-refractory GVHD after stem cell transplant
A microbiome-based therapy is being developed to help people who have graft-versus-host disease that doesn’t respond to standard treatments after a stem cell transplant.
-
Role of altered mitochondria in preventing GVHD after stem cell transplant
This NIH grant explores how damaged mitochondria released during pre-transplant conditioning may trigger graft-versus-host disease and tests ways to fix mitochondrial dynamics to prevent GVHD.
-
Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
-
Using medium-chain fatty acids and a fat-sensing receptor to treat chronic graft-versus-host disease
This project looks at whether changing medium‑chain fatty acids or blocking a fat sensor called GPR84 can help people with chronic graft‑versus‑host disease after a bone marrow/stem cell transplant.
-
Microbiome-based oral therapy for gut GVHD after stem cell transplant
Researchers are testing an oral live Biotherapeutic Product to help the gut microbiome improve graft-versus-host disease after stem cell transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.